Market News & Trends
EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III & Stage IV Non-Small Cell Lung Cancer
EQRx, Inc. recently announced data from its partner CStone Pharmaceuticals’ two pivotal Phase 3 studies of the anti-PD-L1 monoclonal antibody sugemalimab for the treatment of…
Clinical Trial Begins in the UK to Investigate 3-in-1 High Blood Pressure Pill
George Medicines recently announced its proprietary triple low-dose combination pill, GMRx2, will be trialed in UK patients with high blood pressure (hypertension), in a collaboration…
Evelo Biosciences Presents Data on EDP1815 Mechanism of Action & Supporting Ongoing Clinical Development for Inflammatory Diseases
Evelo Biosciences, Inc. recently announced data for EDP1815, the company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis…..
Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study
Imcyse recently reported positive biomarker data from a planned interim analysis of its Phase 2 study, IMCY-0098 Proof of ACtion in Type 1 Diabetes (T1D) (IMPACT), evaluating the company’s lead candidate….
Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio From DeuteRx, LLC
Salarius Pharmaceuticals, Inc. recently announced a definitive agreement with DeuteRx, LLC to acquire an oral, small molecule targeted protein degradation portfolio. The acquisition includes a lead….
Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK & Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity
Rhythm Pharmaceuticals, Inc. recently announced the first patient has been dosed with setmelanotide, the company’s melanocortin-4 receptor (MC4R) agonist, in the Phase 2 DAYBREAK clinical…
Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio
Brooklyn ImmunoTherapeutics, Inc. recently announced 18 new patents were issued and 17 new patent applications were filed in 2021. The intellectual property is owned by…
Proscia & Datavant Partner to Connect Pathology Data With Health Data Ecosystem for Life Sciences R&D
Proscia and Datavant recently announced a partnership that will provide life sciences companies with digitized pathology data to power the development of novel therapeutics and diagnostics.…
INCOG BioPharma Services Builds State-of-the-Art Facility With Promise to Deliver a Better Customer Experience
INCOG BioPharma Services is nearing completion on the construction of its manufacturing facility and global headquarters in Fishers, Indiana. The 90,000-sq-ft facility will be the…
Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin-Based Adjuvants for Life-Saving Vaccines
Q-VANT Biosciences has launched as the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants including QS-21. QS-21 is considered the “Gold Standard” adjuvant for enhancing immune….
HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia
HUTCHMED (China) Limited recently announced the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to HMPL-523,…
COVAXIN (BBV152) Booster Shown to Neutralize Both Omicron & Delta Variants of SARS-CoV-2
Ocugen, Inc.and its partner, Bharat Biotech recently announced results from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of candidate vaccine….
atai Life Sciences Announces FDA IND Clearance for PCN-101 R-ketamine Program
atai Life Sciences N.V. recently announced the US FDA has given Investigational New Drug (IND) clearance to conduct a clinical DDI study of PCN-101 (R-ketamine). atai plans to initiate the….
Zai Lab Announces First Patient Treated in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer
Zai Lab Limited recently announced treatment of the first patient in Greater China in the PANOVA-3 trial, a Phase 3 pivotal trial of Tumor Treating…
Catalent Increases Specialized Packaging Capabilities at its Philadelphia Facility to Support Growing Biologic & Cell & Gene Therapy Markets
Catalent recently announced it has increased cold chain packaging capabilities at its Philadelphia facility to support increased demand for the distribution of biologic drugs, and…
Definitive Agreement to Acquire Exelead Will Strengthen the CDMO Offering for mRNA of the Life Science Business of Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany recently announced the signing of a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately…
SK Inc., the Second Largest Conglomerate in South Korea, Has Invested $350 Million in the Center for Breakthrough Medicines
The Center for Breakthrough Medicines recently announced it has received $350 million in equity financing from SK Inc.. CBM is partnering with SK to create…
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
Sana Biotechnology, Inc., IASO Biotherapeutics, and Innovent Biologics recently announced the companies entered into an agreement pursuant to which Sana obtained from IASO Bio and Innovent non-exclusive commercial rights to a clinically validated fully-human BCMA CAR construct for use in certain….
NeoCura & PhoreMost Announce Research Collaboration to Explore Novel Cancer Therapeutics
NeoCura Bio-Medical Technology Co., Ltd. and PhoreMost Limited recently announced an oncology drug discovery research collaboration. As part of the collaboration, PhoreMost’s SITESEEKER phenotypic screening platform and NeoCura’s full-process RNA drug design platform will….
Black Diamond Therapeutics Announces FDA Allowance of IND Application for a MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma & Non-Small Cell Lung Cancer
Black Diamond Therapeutics, Inc. recently announced the US FDA has cleared an investigational new drug (IND) application for its MasterKey inhibitor BDTX-1535, an irreversible, mutant…
